MAGENTA THERAPEUTICS INC (MGTA)
US55910K1088 - Common Stock
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MGTA, FRG, EMAN
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MGTA, CHRA, STSA
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Moore Kuehn Encourages RUTH, MGTA, MDWT, and CBOF Investors to Contact Law Firm
/PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RUTH, MGTA, OPCH, AMED
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Shareholder Alert: Ademi LLP investigates whether Magenta Therapeutics, Inc. has obtained a Fair Price in its transaction with Dianthus
/PRNewswire/ -- Ademi LLP is investigating Magenta (Nasdaq: MGTA) for possible breaches of fiduciary duty and other violations of law in its transaction with...
Magenta Therapeutics stock to merge with Dianthus in all-stock deal (NASDAQ:MGTA)
Magenta Therapeutics (MGTA) has agreed to combine with privately-held clinical-stage biotech Dianthus Therapeutics in an all-stock deal. Read the full story here.
Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement
Merger to create Nasdaq-listed, clinical-stage biotechnology company focused on advancing Dianthus’ portfolio of next-generation antibody complement...
Magenta stock adopts stockholder rights plan (NASDAQ:MGTA)
Magenta Therapeutics (MGTA) announced Friday a stockholder rights plan for one year to cut likelihood of unwanted bids for the company ownership. Read more here.
Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan
CAMBRIDGE, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics, Inc. (Nasdaq: MGTA) (“Magenta” or the “Company”) today announced that its...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Good morning! It's time to start the final day of trading this week with a look at the biggest pre-market stock movers for Friday!
Magenta Therapeutics up 47% on plan to pursue strategic alternatives (NASDAQ:MGTA)
Magenta Therapeutics (MGTA) has added 47% in post-market trading after saying it will stop development of its program and conduct a review of strategic alternatives.
Magenta Therapeutics to Explore Strategic Alternatives
CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company focused on improving stem...
MGTA stock cut to Neutral at Wedbush as leukemia trial comes to a pause (NASDAQ:MGTA)
Magenta Therapeutics (MGTA) lost ~11% Thursday as Wedbush downgraded it citing a decision to pause Phase 1/2 dose-escalation trial for blood cancer drug MGTA-117. Read the full story here.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're starting off the day with an overview of the biggest pre-market stock movers that traders need to watch on Thursday!
Magenta Therapeutics pauses leukemia trial following participant death (NASDAQ:MGTA)
Magenta Therapeitics (MGTA) has halted a phase 1/2 trial of MGTA-117 for acute myeloid leukemia and myelodysplastic syndrome following the death of a patient that nay be related to the drug
Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety
CAMBRIDGE, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA) today announced that the latest participant dosed at the Cohort 3...